Please assess the completion status of the following clinical trial:

Trial Title: Pregnenolone in the Management of Schizophrenia Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* DSM-IV criteria for schizophrenia or schizoaffective disorder~* Ability and willingness to sign informed consent for participation in the study~Exclusion Criteria:~* Evidence of organic brain damage, mental retardation, alcohol or drug abuse~* Prostate nodules or cancer.~* Moderate symptoms of benign prostatic hypertrophy such as hesitancy, urgency, frequent voiding and feeling of incomplete voiding.~* History of ischemic cardiac disease.~* Renal disease.~* Hepatic dysfunction.~* Women with a history of carcinoma of the breast, or any women with a family history of the following: premenopausal breast cancer or bilateral breast cancer in a first degree relative; multiple family members (greater than three relatives) with postmenopausal breast cancer.~* Women with a history of uterine cancer.~* Patients with a known hypersensitivity to androgens.~* Pregnant women.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).